Skip to content
Open access · CC-BY via OpenAlex

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection

Jiří Patočka, Kamil Kuča, Patrik Olekšák, Eugenie Nepovimová, Martin Vališ, Michal Novotný, Blanka Klímová

Pharmaceuticals · 2021 · ▲ 44 citations

Abstract

Since December 2019, SARS-CoV-2 (COVID-19) has been a worldwide pandemic with enormous consequences for human health and the world economy. Remdesivir is the only drug in the world that has been approved for the treating of COVID-19. This drug, as well as vaccination, still has uncertain effectiveness. Drug repurposing could be a promising strategy how to find an appropriate molecule: mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) could be one of them. The authors performed a systematic literature review of available studies on the research describing rapamycin in association with COVID-19 infection. Only peer-reviewed English-written articles from the world's acknowledged databases Web of Science, PubMed, Springer and Scopus were involved. Five articles were eventually included in the final analysis. The findings indicate that rapamycin seems to be a suitable candidate for drug repurposing. In addition, it may represent a better candidate for COVID-19 therapy than commonly tested antivirals. It is also likely that its efficiency will not be reduced by the high rate of viral RNA mutation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3390/ph14030217
Canonical
link ↗
Fetched
2026-10-29 MST

Cite this

APA
Patočka, J., Kuča, K., Olekšák, P., Nepovimová, E., Vališ, M., Novotný, M., &amp; Klímová, B. (2021). Rapamycin: Drug Repurposing in SARS-CoV-2 Infection. <em>Pharmaceuticals</em>. https://doi.org/10.3390/ph14030217
Vancouver
Patočka J, Kuča K, Olekšák P, Nepovimová E, Vališ M, Novotný M, et al. Rapamycin: Drug Repurposing in SARS-CoV-2 Infection. Pharmaceuticals. 2021. doi:10.3390/ph14030217.
BibTeX
@article{ji2021Rapamy, title = {Rapamycin: Drug Repurposing in SARS-CoV-2 Infection}, author = {Jiří Patočka and Kamil Kuča and Patrik Olekšák and Eugenie Nepovimová and Martin Vališ and Michal Novotný and Blanka Klímová}, journal = {Pharmaceuticals}, year = {2021}, doi = {10.3390/ph14030217}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings